Moreover, pro-inflammatory cytokines in the liver were demonstrated to be mediated by activated Tlr9 along within NASH progression, where Tlr9 antagonist IRS954 could block this process.325. This evidence concerns the gene TLR9 and metabolic dysfunction-associated steatohepatitis.